WO2013100772A1 - The use of vitamin d analogues in combination with imatinib in therapy of non-small cell lung cancer - Google Patents

The use of vitamin d analogues in combination with imatinib in therapy of non-small cell lung cancer Download PDF

Info

Publication number
WO2013100772A1
WO2013100772A1 PCT/PL2012/000134 PL2012000134W WO2013100772A1 WO 2013100772 A1 WO2013100772 A1 WO 2013100772A1 PL 2012000134 W PL2012000134 W PL 2012000134W WO 2013100772 A1 WO2013100772 A1 WO 2013100772A1
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib
vitamin
analogues
lung cancer
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PL2012/000134
Other languages
English (en)
French (fr)
Inventor
Joanna Wietrzyk
Beata FILIP-PSURSKA
Andrzej Kutner
Wiesław SZELEJEWSKI
Michał CHODYŃSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instytut Farmaceutiyczny
Original Assignee
Instytut Farmaceutiyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Farmaceutiyczny filed Critical Instytut Farmaceutiyczny
Publication of WO2013100772A1 publication Critical patent/WO2013100772A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the use of vitamin D analogues in combination with tyrosine kinase inhibitor imatinib in therapy of non-small cell lung cancer.
  • Fig, l A depicts kinetics of a tumour growth in mice (all groups) with non-small cell lung cancer A54 treated with imatinib (GV) (50 mg/kg daily) in combination with analogues of vitamin D.
  • GV imatinib
  • PRI-2191 dose 1 ⁇ g/kg day, administered subcutaneousl per half of body weight, multiple administration, 3 times per week (on days 10, 12, 14, 17, 19, 21 , 24, 26, 28).
  • tumour growth inhibition was carried out by analysis of percent of inhibition in individual combinations of compounds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/PL2012/000134 2011-12-30 2012-12-30 The use of vitamin d analogues in combination with imatinib in therapy of non-small cell lung cancer Ceased WO2013100772A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397662A PL226174B1 (pl) 2011-12-30 2011-12-30 Polaczenie analogu witaminy D z imatinibem do stosowania w leczeniu skojarzonym niedrobnokomorkowego raka pluc
PLP-397662 2011-12-30

Publications (1)

Publication Number Publication Date
WO2013100772A1 true WO2013100772A1 (en) 2013-07-04

Family

ID=47666456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2012/000134 Ceased WO2013100772A1 (en) 2011-12-30 2012-12-30 The use of vitamin d analogues in combination with imatinib in therapy of non-small cell lung cancer

Country Status (2)

Country Link
PL (1) PL226174B1 (pl)
WO (1) WO2013100772A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
B FILIP-PSURSKA ET AL: "Vitamin D analogs enhance the activity of imatinib mesylate in human non-small cell lung cancer model", VIII MULTIDYSCYPLINARNA KONFERENCJA NAUKI O LEKU, 30 May 2012 (2012-05-30), pages 1 - 3, XP055061414 *
BAUMAN J.E. ET AL.: "Antagonism of Platelet-Derived Growth Factor Receptor in Non-Small Cell Lung Cancer: Rationale and Investigations", CLIN CANCER RES, vol. 13, no. 15, 1 August 2007 (2007-08-01)
BAUMAN JE. ET AL.: "Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations", CLIN.CANCER RES., vol. 13, 2007, pages 4632 - 4636
CHUNG 1 ET AL.: "Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo", CANCER RES, vol. 69, pages 967 - 975, XP055061350, DOI: doi:10.1158/0008-5472.CAN-08-2307
DIAZ G.D. ET AL.: "Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy", CANCER RES, vol. 60, 2000, pages 2304 - 2312
G VLAHOVIC ET AL: "Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-[beta] and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation", BRITISH JOURNAL OF CANCER, vol. 95, no. 8, 26 September 2006 (2006-09-26), pages 1013 - 1019, XP055061342, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6603366 *
G. W. KRYSTAL ET AL., CLIN. CANCER RES., vol. 8, no. 11, 2000, pages 3319 - 3326
J WIETRZYK ET AL: "The Antitumor Effect of Lowered Doses of Cytostatics Combined with New Analogs of Vitamin D in Mice", ANTICANCER RESEARCH, vol. 27, no. 5A, September 2007 (2007-09-01), pages 3387 - 3398, XP055061481, ISSN: 0250-7005 *
LEVINA V ET AL.: "Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop", CANCER RES., vol. 70, 2010, pages 338 - 346
MA Y. ET AL.: "Vitamin D in combination cancer treatment", JOURNAL OF CANCER, vol. 1, 2010, pages 101 - 107
MANTUR M.; KOPER 0.: "Plytkopochodny czynnik wzrostu - budowa, rola ijego receptory", POL. MERK. LEK., vol. XXIV, no. 140, 2008, pages 173
PELCZYNSKA MARZENA ET AL: "Antiproliferative activity of vitamin D compounds in combination with cytostatics", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 26, no. 4A, July 2006 (2006-07-01), pages 2701 - 2705, XP009161120, ISSN: 0250-7005 *
PETERS G.J. ET AL., PHARMACOL THER, vol. 87, 2000, pages 227 - 253
R. RENGAN ET AL: "New Strategies in Non-Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease", CLINICAL CANCER RESEARCH, vol. 17, no. 13, 16 May 2011 (2011-05-16), pages 4192 - 4199, XP055061484, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2760 *
REITERER G; YEN A.: "Platelet-derived growth factor receptor regulates myeloid and monocytic differentiation of HL-60 cells", CANCER RES., vol. 67, 2007, pages 7765 - 7772
SWITALSKA M ET AL.: "The in-vitro antiproliferative effect of PRl-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells", ANTICANCER DRUGS, 2011
SWITALSKA MARTA ET AL: "The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells", ANTI-CANCER DRUGS, vol. 23, no. 1, January 2012 (2012-01-01), pages 70 - 80, XP009169251, ISSN: 0959-4973 *
V/AHOVIC G. ET AL.: "Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation", BR.J CANCER, vol. 95, 2006, pages 1013 - 1019, XP055061342, DOI: doi:10.1038/sj.bjc.6603366
VLAHOVIC G. ET AL.: "Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation", BR.J.CANCER, vol. 95, 2006, pages 1013 - 1019, XP055061342, DOI: doi:10.1038/sj.bjc.6603366
VLAHOVIC G. ET AL.: "Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation", BR.JCANCER, vol. 95, 2006, pages 1013 - 1019, XP055061342, DOI: doi:10.1038/sj.bjc.6603366
WANG W.L: "Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571", ONCOGENE, vol. 19, 2000, pages 3521 - 3528, XP002978442, DOI: doi:10.1038/sj.onc.1203698
WIETRZYK J. ET AL.: "The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics", ONCOL RES, vol. 16, 2007, pages 517 - 525, XP009169252, DOI: doi:10.3727/096504007783438330
WIETRZYK JOANNA ET AL: "The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics", ONCOLOGY RESEARCH, vol. 16, no. 11, 2007, pages 517 - 525, XP009169252, ISSN: 0965-0407 *
ZHANG P. ET AL.: "Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro", MOL. CANCER, vol. 2, 2003, pages 1, XP021018247, DOI: doi:10.1186/1476-4598-2-1

Also Published As

Publication number Publication date
PL397662A1 (pl) 2013-07-08
PL226174B1 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
DK2786754T3 (en) Combination therapy with a mitotic inhibitor
ES3064856T3 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
ES2741399T3 (es) Apilimod para el uso en el tratamiento de cáncer renal
US20230181565A1 (en) Crenolanib combination therapy
US10765682B2 (en) Apilimod for use in the treatment of melanoma
CA2960989A1 (en) Human dosing of phosphatase inhibitor
EP2892535B1 (en) Method of adjuvant cancer treatment
US20200352937A1 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use
US20240285640A1 (en) Combination therapy for treating pik3ca-mutated cancer
US10220072B2 (en) Mesalamine for the treatment of cancer
Greystoke et al. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
US20150297623A1 (en) Methods for treatment of primary cancer and cancer metastasis
US10238679B2 (en) Antitumor activity of multi-kinase inhibitors in colorectal cancer
US20150110864A1 (en) Novel antitumor agent comprising combination of three agents
PL226174B1 (pl) Polaczenie analogu witaminy D z imatinibem do stosowania w leczeniu skojarzonym niedrobnokomorkowego raka pluc
US20090270340A1 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
CA2894153A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
WO2025232723A1 (en) Treatment method with focal adhesion kinase inhibitor
WO2024088193A1 (en) Combination of aurora a and parp inhibitors for treatment of cancers
US20150374702A1 (en) Anticancer adjuvant containing pentoxifylline
HK40070843A (en) Dabrafenib and trametinib in a method of adjuvant cancer treatment
TW202126298A (zh) 用於癌症治療之組合及其應用
Greystoke et al. combination with carboplatin given on day 1 alone in patients with advanced solid tumours
HK1240937A1 (en) Small molecules for the treatment of primary cancer and cancer metastasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12821331

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12821331

Country of ref document: EP

Kind code of ref document: A1